Inflammation and asymmetric dimethylarginine for predicting death and cardiovascular events in ESRD patients.
Standard
Inflammation and asymmetric dimethylarginine for predicting death and cardiovascular events in ESRD patients. / Tripepi, Giovanni; Francesco, Mattace Raso; Sijbrands, Eric; Seck, Mohamed Sidy; Maas, Renke; Böger, Rainer; Witteman, Jacqueline; Rapisarda, Francesco; Malatino, Lorenzo; Mallamaci, Francesca; Zoccali, Carmine.
In: CLIN J AM SOC NEPHRO, Vol. 6, No. 7, 7, 2011, p. 1714-1721.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Inflammation and asymmetric dimethylarginine for predicting death and cardiovascular events in ESRD patients.
AU - Tripepi, Giovanni
AU - Francesco, Mattace Raso
AU - Sijbrands, Eric
AU - Seck, Mohamed Sidy
AU - Maas, Renke
AU - Böger, Rainer
AU - Witteman, Jacqueline
AU - Rapisarda, Francesco
AU - Malatino, Lorenzo
AU - Mallamaci, Francesca
AU - Zoccali, Carmine
PY - 2011
Y1 - 2011
N2 - Endothelial dysfunction as assessed by asymmetric dimethylarginine (ADMA) and inflammation has been consistently linked to atherosclerosis, death, and cardiovascular (CV) events in ESRD patients. Inflammation amplifies the effect of ADMA on the severity of atherosclerosis in ESRD patients, but it is still unknown whether inflammation and ADMA interact in the high risk of death and CV events in this population.
AB - Endothelial dysfunction as assessed by asymmetric dimethylarginine (ADMA) and inflammation has been consistently linked to atherosclerosis, death, and cardiovascular (CV) events in ESRD patients. Inflammation amplifies the effect of ADMA on the severity of atherosclerosis in ESRD patients, but it is still unknown whether inflammation and ADMA interact in the high risk of death and CV events in this population.
KW - Adult
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Middle Aged
KW - Risk Factors
KW - Cohort Studies
KW - Prognosis
KW - Risk Assessment
KW - Time Factors
KW - Proportional Hazards Models
KW - Chi-Square Distribution
KW - Analysis of Variance
KW - C-Reactive Protein/metabolism
KW - Arginine/analogs & derivatives/blood
KW - Biological Markers/blood
KW - Cardiovascular Diseases/blood/immunology/mortality
KW - Inflammation/blood/immunology/mortality
KW - Inflammation Mediators/blood
KW - Interleukin-6/blood
KW - Italy/epidemiology
KW - Kidney Failure, Chronic/blood/immunology/mortality/therapy
KW - Renal Dialysis/adverse effects/mortality
KW - Adult
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Middle Aged
KW - Risk Factors
KW - Cohort Studies
KW - Prognosis
KW - Risk Assessment
KW - Time Factors
KW - Proportional Hazards Models
KW - Chi-Square Distribution
KW - Analysis of Variance
KW - C-Reactive Protein/metabolism
KW - Arginine/analogs & derivatives/blood
KW - Biological Markers/blood
KW - Cardiovascular Diseases/blood/immunology/mortality
KW - Inflammation/blood/immunology/mortality
KW - Inflammation Mediators/blood
KW - Interleukin-6/blood
KW - Italy/epidemiology
KW - Kidney Failure, Chronic/blood/immunology/mortality/therapy
KW - Renal Dialysis/adverse effects/mortality
M3 - SCORING: Journal article
VL - 6
SP - 1714
EP - 1721
JO - CLIN J AM SOC NEPHRO
JF - CLIN J AM SOC NEPHRO
SN - 1555-9041
IS - 7
M1 - 7
ER -